Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers
Rattachement africain : au, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Gynecological and obstetric infectious diseases are crucial to women’s health. There is growing evidence that links the presence of Fusobacterium nucleatum (F. nucleatum), an anaerobic oral commensal and potential periodontal pathogen, to the development and progression of various human diseases, including cancers. While the role of this opportunistic oral pathogen has been extensively studied in colorectal cancer in recent years, research on its epidemiological evidence and mechanistic link to gynecological diseases (GDs) is still ongoing. Thus, the present review, which is the first of its kind, aims to undertake a comprehensive and critical reappraisal of F. nucleatum, including the genetics and mechanistic role in promoting adverse pregnancy outcomes (APOs) and various GDs, including cancers. Additionally, this review discusses new conceptual advances that link the immunomodulatory role of F. nucleatum to the development and progression of breast, ovarian, endometrial, and cervical carcinomas through the activation of various direct and indirect signaling pathways. However, further studies are needed to explore and elucidate the highly dynamic process of host–F. nucleatum interactions and discover new pathways, which will pave the way for the development of better preventive and therapeutic strategies against this pathobiont.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers
- Date Crossref
- 20/04/2024
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hunter Medical Research Institute Drug Repurposing and Medicines Research Program pays non établi dans la noticeStructure de recherche
-
University of Newcastle Australia pays non établi dans la noticeUniversité ou école supérieure
-
John Hunter Hospital Hunter New England Centre for Gynecological Cancer pays non établi dans la noticeÉtablissement de santé
-
Calvary Mater Newcastle Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Pittsburgh Department of Immunology pays non établi dans la noticeUniversité ou école supérieure
-
School of Biomedical Sciences and Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine and Public Health pays non établi dans la noticeUniversité ou école supérieure
-
Newcastle Private Hospital pays non établi dans la noticeÉtablissement de santé
Drug Repurposing and Medicines Research Program — Hunter Medical Research Institute, University of Newcastle Australia et Hunter New England Centre for Gynecological Cancer — John Hunter Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.